Theralase(r) commences non-brokered private placement and termination of previously announced financing

Toronto, on / accesswire / november 17, 2023 / theralase® technologies inc. ("theralase®" or the "company") (tsxv:tlt)(otcqb:tltff), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated photo dynamic compounds ("pdcs") used for the safe and effective destruction of various cancers, bacteria and viruses, has commenced a non-brokered private placement of units of the company ("units") to raise up to $can 1.5 m ("offering"). in the offering, each unit is priced at $can 0.22 and consists of one common share of the company ("common share") and one common share purchase warrant ("warrant").
CAN Ratings Summary
CAN Quant Ranking